Syros Pharmaceuticals (NASDAQ:SYRS) Earns Sell Rating from Analysts at StockNews.com
StockNews.com began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a research report sent to investors on Saturday morning. The firm issued a sell rating on the stock. A number of other equities research analysts also recently commented on the stock. JMP Securities restated a “market perform” rating on shares of Syros […]
More Stories
Iran War Pushes Gulf Allies to Request Dollar Help—What to Know
By Andrew Moran Treasury Secretary Scott Bessent confirmed last week that several U.S. allies in the Gulf region and Asia...
DC Shooting Suspect Charged With Attempting to Assassinate Trump
By Stacy Robinson and Jackson Richman WASHINGTON—The Department of Justice has charged Cole Allen, the suspect in the White House...
United Arab Emirates to Leave OPEC Next Month
By Andrew Moran The United Arab Emirates said it is leaving OPEC and the broader alliance. “This decision follows a...
Improper US Government Payments Rose to $186 Billion in 2025: Watchdog
By Sylvia Xu Federal government agencies reported a total estimate of about $186 billion in improper payments in fiscal year...
US Homebuilders Lean on Incentives to Unload Homes in Challenging Market
By Panos Mourdoukoutas Homebuilder earnings reports released in recent days point to a challenging environment for the industry, as companies...
Shell to Buy ARC Resources in $16.4 Billion Deal to Expand Canada Output
By Bill Pan Shell is set to buy ARC Resources in a move that would expand the British oil major’s...